These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17332346)

  • 21. Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
    Peralba JM; DeGraffenried L; Friedrichs W; Fulcher L; Grünwald V; Weiss G; Hidalgo M
    Clin Cancer Res; 2003 Aug; 9(8):2887-92. PubMed ID: 12912932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
    Ku BM; Yi SY; Koh J; Bae YH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Oncotarget; 2016 Mar; 7(12):14803-13. PubMed ID: 26909611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model.
    Czerninski R; Amornphimoltham P; Patel V; Molinolo AA; Gutkind JS
    Cancer Prev Res (Phila); 2009 Jan; 2(1):27-36. PubMed ID: 19139015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro.
    Li Q; Song XM; Ji YY; Jiang H; Xu LG
    Biochem Biophys Res Commun; 2013 Nov; 440(4):701-6. PubMed ID: 24103749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
    Xie J; Li Q; Ding X; Gao Y
    Cell Physiol Biochem; 2018; 46(2):676-686. PubMed ID: 29621758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
    Neshat MS; Mellinghoff IK; Tran C; Stiles B; Thomas G; Petersen R; Frost P; Gibbons JJ; Wu H; Sawyers CL
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10314-9. PubMed ID: 11504908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Curcumin inhibits carcinogen and nicotine-induced Mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma.
    Clark CA; McEachern MD; Shah SH; Rong Y; Rong X; Smelley CL; Caldito GC; Abreo FW; Nathan CO
    Cancer Prev Res (Phila); 2010 Dec; 3(12):1586-95. PubMed ID: 20851953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
    Coppock JD; Wieking BG; Molinolo AA; Gutkind JS; Miskimins WK; Lee JH
    Neoplasia; 2013 Jun; 15(6):620-30. PubMed ID: 23730210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wild-type phosphatase and tensin homolog deleted on chromosome 10 improved the sensitivity of cells to rapamycin through regulating phosphorylation of Akt in esophageal squamous cell carcinoma.
    Lu Z; Wang J; Zheng Y; Yang S; Liu M; Chen X; Wang C; Hou G
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26725440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indications for an alternative effective treatment of head and neck squamous cell carcinoma with temsirolimus plus bevacizumab: from bench to bedside?
    Trafalis DT; Alifieris C; Dalezis P; Geromichalos G; Sitaras NM
    Anticancer Drugs; 2012 Sep; 23(8):874-82. PubMed ID: 22510794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
    Han S; Khuri FR; Roman J
    Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
    Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
    Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts.
    Bozec A; Etienne-Grimaldi MC; Fischel JL; Sudaka A; Toussan N; Formento P; Milano G
    Oral Oncol; 2011 May; 47(5):340-4. PubMed ID: 21421338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option.
    Klinghammer K; Raguse JD; Plath T; Albers AE; Joehrens K; Zakarneh A; Brzezicha B; Wulf-Goldenberg A; Keilholz U; Hoffmann J; Fichtner I
    Int J Cancer; 2015 Jun; 136(12):2940-8. PubMed ID: 25404014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer.
    Mao L; Deng WW; Yu GT; Bu LL; Liu JF; Ma SR; Wu L; Kulkarni AB; Zhang WF; Sun ZJ
    Int J Cancer; 2017 Mar; 140(5):1173-1185. PubMed ID: 27798955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and comparative effectiveness of sirolimus as an anticancer drug.
    Hu M; Ekshyyan O; Herman Ferdinandez L; Rong X; Caldito G; Nathan CO
    Laryngoscope; 2011 May; 121(5):978-82. PubMed ID: 21520111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
    Galanis E; Buckner JC; Maurer MJ; Kreisberg JI; Ballman K; Boni J; Peralba JM; Jenkins RB; Dakhil SR; Morton RF; Jaeckle KA; Scheithauer BW; Dancey J; Hidalgo M; Walsh DJ;
    J Clin Oncol; 2005 Aug; 23(23):5294-304. PubMed ID: 15998902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin.
    Liu J; Kuo WL; Seiwert TY; Lingen M; Ciaccio MF; Jones RB; Rosner MR; Cohen EE
    Head Neck; 2011 Dec; 33(12):1774-82. PubMed ID: 21438065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line.
    DeFatta RJ; Nathan CO; De Benedetti A
    Laryngoscope; 2000 Jun; 110(6):928-33. PubMed ID: 10852506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
    Panwalkar A; Verstovsek S; Giles FJ
    Cancer; 2004 Feb; 100(4):657-66. PubMed ID: 14770419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.